This report on the nanobiotechnology market studies various technologies and applications. Nanobiotechnology deals with biological and biochemical applications. Nanobiotechnology mostly studies existing elements of living organisms and nature to fabricate new nanodevices. The potential uses and benefits of nanotechnology are vast.
The major applications of nanobiotechnology exist in the biomedical field. They are primarily targeted toward developing novel drug delivery systems, which are expected to remain the major application of nanobiotechnology throughout the forecast period.
For this study, the global nanobiotechnology market is segmented based on technology type into nanoparticles, nanocrystals, quantum dots, liposomes, polymer structures (dendrimers), nanopores, and integrated nanostructures. Market size estimates and forecasts for these segments for 2013–2023 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for 2016–2023, considering 2015 as the base year.
The nanobiotechnology market is segmented based on application type: drug delivery, sequencing, biologic imaging, research tools, and microbicide. Market size estimates and forecasts for these segments for 2013–2023 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for 2016–2023, considering 2015 as the base year.
The nanobiotechnology market has been geographically categorized into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, and the GCC countries. The market size and forecast for these segments during 2013–2023 and their CAGRs for the period 2016–2023 are provided in this report.
The major key players profiled in the nanobiotechnology market are based on characteristics such as business description, financial health, budget allocation, product portfolio, and news coverage. The key players profiled in this report are Aduro BioTech, Calando Pharmaceuticals Inc., Baxter International, Inc., Fresenius Kabi AG, Smith & Nephew plc, Biosante Phosphate Pharmaceuticals Inc., Celgene Corporation, Elan Pharmaceuticals Inc., Flamel Technologies Inc., Nanophase Technologies Corporation, Sigma Aldrich Company, Dendritic Nanotechnologies Inc., and SkyePharma Pharmaceuticals.
Based on the type of application, the global nanobiotechnology market is segmented as follows:
- Drug Delivery
- Biologic Imaging
- Research Tools
On the basis of application, the nanobiotechnology market is segmented into drug delivery, sequencing, biological imaging, research tools, and microbicide. In 2015, drug delivery and sequencing segments were observed as the largest segments of nanobiotechnology, accounting for a market share of around 55%. Biotechnology and pharmaceutical industries are expected to remain the largest end-users of Nanobiotechnology.
Market experts suggested that drug delivery is the most crucial pharmaceutical application and that nanobiotechnology is now the most focused area in this field. In drug delivery applications, apart from solving solubility issues of the drug, it also helps enhance intracellular delivery possibilities and the level of skin permeability in transdermal drug delivery. Thus, nanobiotechnology possesses the potential to develop breakthrough interface systems that allow interaction between novel electronic devices and biological systems.
Based on the type of technology, the nanobiotechnology market is segmented into:
- Quantum dots
- Polymer Structures: Dendrimers
- Integrated Nanostructures
In 2015, the segments liposomes and polymer-structured dendrimers collectively accounted for the major market share of around 50%. They were expected to maintain their dominance throughout the forecast period. The rising prevalence of cancer, increasing public awareness related to novel treatments for cancer, and constant technological upgradation in the field of nanotechnology research and development.
The major restraints on this market, especially in emerging and underdeveloped economies, are scarcity of resources and mounting technological costs. However, rising pharmaceutical demand is expected to open up novel growth opportunities within the forecast period. Market experts suggest that nanobiotechnology also possesses the capability to develop breakthrough interface systems between physical objects and living cells to allow interaction between modern electronic devices and biological systems. The decades of in-depth research and development in nanobiotechnology are now assisting access to novel avenues of healthcare, such as the synthesis of advanced nanofabricated systems and devices for treating several untreatable diseases.
For this study, the global nanobiotechnology market is categorized into three segments:
- North America
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
In the base year of 2015, North America accounted for the largest share of the global nanobiotechnology market, followed by Europe, Asia-Pacific, LATAM, and MEA. However, the Asia-Pacific region (comprising Japan, China, and India as major countries) is anticipated to grow at the fastest CAGR during the forecast period of 2016–202. The key factors assisting the growth of the nanobiotechnology market in North America and Europe are the rising prevalence of cancer, the high acceptance rate of novel modes of treatment, the high accessibility to advanced healthcare infrastructure, and a favorable environment for nanobiotechnology–based research and development.
Asia-Pacific was observed as the fastest-growing region throughout the forecast period of 2016–2023 due to rising public awareness related to cancer diagnosis and treatment, developing healthcare services and research and development infrastructure, and high market penetration and acceptance of novel treatment technologies. The major restraints on this market, especially in emerging and underdeveloped economies, are scarcity of resources and mounting technological costs. However, rising pharmaceutical demand is expected to open up novel growth opportunities within the forecast period.